Dana-Farber Cancer Institute has executed a letter of intent to establish a new ambulatory cancer center at 60 Guest St. in the Brighton neighborhood, within the Boston Landing development. The plan was disclosed by CEO and president Benjamin L. Ebert in a LinkedIn post, which noted that the project remains subject to regulatory review.
The institution is targeting a summer 2029 opening for the facility, contingent on receiving the necessary approvals. The ambulatory center would be located within a 350,000-square-foot property at Boston Landing, although Dana-Farber has not stated how much of that space it expects to occupy.
Ebert said the planned site is designed to support a broad range of cancer services. Program elements outlined for the new ambulatory center include exam rooms, infusion services, an on-site pharmacy, radiology, and laboratory capabilities. The facility is also expected to host clinical trials to support what Ebert described as multidisciplinary cancer care.
Specific project costs have not been released, and Dana-Farber has not provided information on the capital structure behind the initiative. The organization has also not disclosed further details about design, construction timeline beyond the anticipated opening season, or the development team that will deliver the space within the Boston Landing property.
In explaining the rationale for the new center, Ebert cited rising cancer incidence and growing demand for Dana-Farber's services. He noted that more patients are turning to the institution for oncology care and framed the planned Boston Landing facility as a way to expand access while maintaining care quality standards.
A Dana-Farber spokesperson told the Boston Business Journal that the Boston Landing ambulatory center will complement existing outpatient locations in Yawkey and Chestnut Hill. Those current ambulatory centers are experiencing higher patient volumes, underscoring the systemwide demand that is contributing to the need for additional capacity.
The announcement positions Boston Landing as a future hub for expanded cancer treatment and research activity once the project advances beyond the letter-of-intent stage and moves through the regulatory process. For now, the initiative signals Dana-Farber's intent to grow its ambulatory footprint in response to patient demand, with further project, leasing, and financial details yet to be disclosed.
